Dupuytren’s Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Diagnosis (Physical Examination, X-ray), Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others)), By Disease Type (Type I, Type II, Type III), By End-use (Hospitals, Clinics, Academic & Research Institute, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.68 Billion
CAGR (2026-2031)	4.66%
Fastest Growing Segment	Treatment
Largest Market	Europe
Market Size (2031)	USD 6.15 Billion

Market Overview

The Global Dupuytren’s Disease Market will grow from USD 4.68 Billion in 2025 to USD 6.15 Billion by 2031 at a 4.66% CAGR. Dupuytren’s disease is a progressive connective tissue disorder characterized by the thickening of the palmar fascia, leading to the formation of collagen nodules and cords that cause permanent finger contractures. The primary drivers supporting market growth include an aging global population and a rising prevalence of associated risk factors such as diabetes, both of which expand the target patient demographic. Furthermore, the increasing availability and patient preference for minimally invasive treatments have broadened the scope of manageable cases. According to the American Society of Plastic Surgeons, in 2024, member surgeons performed 208,480 reconstructive hand surgery procedures, a figure that underscores the substantial and consistent demand for functional interventions including those for Dupuytren’s contracture.

One significant challenge that could impede market expansion is the high rate of disease recurrence associated with available treatments. Whether patients undergo surgical fasciectomy or minimally invasive enzymatic injections, the lack of a permanent cure often necessitates repeat interventions, resulting in a compounded economic burden on payers and patients. This long-term efficacy issue, combined with the stringent reimbursement criteria often applied to high-cost biologic therapies, may limit the adoption of premium treatment options in cost-sensitive healthcare markets.

Key Market Drivers

A surge in research and development for novel therapeutics is a primary engine for growth in the Global Dupuytren’s Disease Market, driven by the urgent need for non-surgical interventions that offer improved safety profiles. Biotechnology firms are actively advancing clinical pipelines to introduce recombinant alternatives to existing collagenase therapies, aiming to reduce dependence on invasive surgical procedures. For instance, according to Connext, July 2024, the company successfully administered the first dose of CNT201 to patients in a Phase 1/2 clinical trial in Australia, marking a critical step toward validating a new genetically recombinant collagenase treatment. This intensification of R&D activity not only promises to diversify the competitive landscape but also aims to broaden market access by developing treatments that may offer superior efficacy or cost advantages over current biologics.

Concurrently, the increasing global prevalence of the condition, particularly among aging demographics, is expanding the volume of patients requiring long-term medical management. As life expectancy rises, the accumulation of lifestyle-related risks and genetic predispositions has led to a measurable increase in diagnosed cases within primary care settings, directly enlarging the addressable patient pool. According to a study released via medRxiv, July 2024, an analysis of general practice registration data identified an overall Dupuytren’s disease prevalence of 1.99% in the studied population, with rates peaking significantly in older age groups. This expanding patient base translates into substantial commercial demand for established pharmaceutical interventions. According to Endo, Inc., in November 2024, the company reported total third-quarter revenues of $128 million for its XIAFLEX franchise, underscoring the significant economic scale fueled by this growing clinical need.

Download Free Sample Report

Key Market Challenges

The high rate of disease recurrence stands as a critical barrier impeding the sustainable growth of the Global Dupuytren’s Disease Market. This clinical reality creates a cycle of repeat interventions that questions the long-term economic value of premium treatment options. Payers and insurance providers are increasingly hesitant to authorize high-cost biologic therapies or minimally invasive procedures when the condition frequently returns, necessitating further medical expenditure. Consequently, this skepticism leads to stringent reimbursement criteria that prioritize traditional, lower-cost surgical methods over innovative but expensive pharmaceutical solutions, thereby limiting revenue potential for manufacturers of novel therapeutics.

According to the British Society for Surgery of the Hand, in 2024, comparative clinical data indicated that patients treated with minimally invasive collagenase injections faced a re-intervention rate of 14.6 percent within one year, whereas those undergoing surgical fasciectomy saw a significantly lower rate of 3.4 percent. This disparity in early efficacy reinforces the reluctance of cost-sensitive healthcare systems to broadly fund advanced non-surgical treatments, directly hampering the market share expansion of premium biological products.

Key Market Trends

The rising adoption of Percutaneous Needle Aponeurotomy (PNA) represents a significant shift toward minimally invasive, cost-effective interventions that prioritize rapid functional recovery over aggressive surgical excision. This trend is gaining momentum as clinicians seek repeatable outpatient procedures that minimize patient downtime and healthcare costs, particularly for cases where traditional open surgery poses disproportionate risks. Recent clinical data validates the efficacy of refined needle techniques in restoring hand function without the extensive rehabilitation required by fasciectomy. According to Musculoskeletal Surgery, January 2025, a study evaluating a modified PNA technique reported a mean contracture correction of 83 percent across affected digits, with a notably low short-term recurrence rate of 14.2 percent, positioning the procedure as a viable first-line treatment for preserving hand mechanics.

Simultaneously, the market is witnessing the integration of adjuvant radiotherapy as a strategic modality to inhibit disease progression and address the challenge of high recurrence rates following primary interventions. This approach marks a move toward hybrid treatment models where radiotherapy is employed immediately after nodule disruption or limited release to deactivate fibroblasts and prevent the reforming of collagen cords. The focus has shifted toward establishing the safety profile of this combination to encourage broader payer coverage and clinical acceptance. According to the Journal of Hand Surgery (European Volume), February 2025, a randomized controlled trial assessing the safety of adjuvant radiotherapy confirmed its tolerability, revealing that 89 percent of recorded adverse events were mild and self-limiting, thereby supporting its role as a low-risk adjunct for long-term disease control.

Segmental Insights

The Treatment segment is currently identified as the fastest-growing category within the Global Dupuytren’s Disease Market. This rapid expansion is primarily driven by the increasing adoption of minimally invasive therapies, particularly enzyme injections using collagenase clostridium histolyticum, which offer reduced recovery times compared to traditional surgeries. Regulatory approvals by authorities such as the U.S. Food and Drug Administration (FDA) have significantly validated these non-surgical alternatives, encouraging broader clinical adoption. Furthermore, a rising geriatric population and growing awareness of therapeutic options continue to fuel the demand for effective interventions, thereby sustaining the strong upward trajectory of this market segment.

Regional Insights

Europe holds a dominant position in the global Dupuytren’s disease market primarily due to the high genetic predisposition among populations of Northern European descent. This demographic factor significantly increases the patient base compared to other regions. Furthermore, the region benefits from a well-established healthcare infrastructure that facilitates early diagnosis and access to corrective procedures. The European Medicines Agency maintains rigorous oversight of therapeutic approvals, ensuring a structured treatment landscape. Consequently, the combination of widespread clinical awareness and accessible medical services sustains Europe as the leading market for these therapies.

Recent Developments

• In July 2025, 180 Life Sciences Corp. announced that the Canadian Intellectual Property Office had issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders using an IL-33 antagonist. This intellectual property achievement strengthened the company's focus on novel anti-fibrotic therapies, specifically for conditions such as Dupuytren’s disease and frozen shoulder, which lack effective non-surgical treatments. The company believed that this development significantly enhanced its proprietary platform and reinforced its strategy to build shareholder value through scientific innovation and patent protection for its legacy assets in the biotechnology sector.
• In July 2024, Connext announced the successful first administration of CNT201, its recombinant collagenase therapeutic, to patients in a Phase 1/2 clinical trial in Australia. This development marked a significant milestone as the company began evaluating the safety, tolerability, and efficacy of the treatment for Dupuytren’s contracture. The trial involved escalating dose levels in patients with the condition, followed by a four-week evaluation period. The Chief Executive Officer of Connext stated that this step offered new hope for a safer and more effective option, positioning the company to potentially provide a fundamental cure for this debilitating fibrotic disorder.
• In March 2024, Ventoux Biosciences announced positive pre-clinical results for its lead compound, VEN-201, and initiated a fundraising round to support further development. The company reported that the study demonstrated desirable anti-fibrotic effects with a positive safety profile, validating the potential of this repurposed small molecule. Ventoux Biosciences aimed to advance this candidate towards regulatory discussions and formulation optimization to address the unmet medical needs in the Dupuytren’s disease market. The organization highlighted its mission to develop disease-modifying therapies that could slow progression in early stages and reduce recurrence after corrective procedures.
• In January 2024, Endo International plc announced that two new presentations regarding Dupuytren’s contracture and its collagenase clostridium histolyticum treatment were shared at the American Association for Hand Surgery annual meeting. The company provided funding for this investigator-initiated research, which aimed to assist healthcare providers in improving patient outcomes. The studies focused on the clinical effectiveness of splinting after injection and the outcomes of managing contractures in specific finger joints. These presentations highlighted the organization's ongoing commitment to advancing medical knowledge and supporting effective non-surgical treatment options for patients suffering from this progressive hand condition in the global market.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Nantong Jinghua Pharmaceutical Co., Ltd
• Actiza Pharmaceutical Private Limited
• Endo International plc
• Spear Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb
• Glaxosmithkline PLC

By Type	By Disease Type	By End-use	By Region
Diagnosis (Physical Examination, X-ray) Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others)	Type I Type II Type III	Hospitals Clinics Academic & Research Institute Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Dupuytren’s Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Dupuytren’s Disease Market, By Type:

• Diagnosis (Physical Examination, X-ray)
• Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others)

• Dupuytren’s Disease Market, By Disease Type:

• Type I
• Type II
• Type III

• Dupuytren’s Disease Market, By End-use:

• Hospitals
• Clinics
• Academic & Research Institute
• Others

• Dupuytren’s Disease Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE